Cellectar Biosciences Inc (CLRB)
2.03
0.00 (0.00%)
USD |
NASDAQ |
Nov 04, 16:00
2.035
0.00 (0.00%)
After-Hours: 20:00
Cellectar Biosciences Enterprise Value: 64.32M for Nov. 4, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 04, 2024 | 64.32M |
| November 01, 2024 | 64.32M |
| October 31, 2024 | 64.73M |
| October 30, 2024 | 65.14M |
| October 29, 2024 | 65.14M |
| October 28, 2024 | 65.14M |
| October 25, 2024 | 64.32M |
| October 24, 2024 | 57.26M |
| October 23, 2024 | 55.11M |
| October 22, 2024 | 57.97M |
| October 21, 2024 | 57.62M |
| October 18, 2024 | 56.90M |
| October 17, 2024 | 55.82M |
| October 16, 2024 | 56.54M |
| October 15, 2024 | 55.11M |
| October 14, 2024 | 56.54M |
| October 11, 2024 | 57.97M |
| October 10, 2024 | 57.26M |
| October 09, 2024 | 55.11M |
| October 08, 2024 | 58.33M |
| October 07, 2024 | 58.69M |
| October 04, 2024 | 60.84M |
| October 03, 2024 | 59.41M |
| October 02, 2024 | 59.41M |
| October 01, 2024 | 56.54M |
| Date | Value |
|---|---|
| September 30, 2024 | 58.69M |
| September 27, 2024 | 55.11M |
| September 26, 2024 | 50.45M |
| September 25, 2024 | 50.80M |
| September 24, 2024 | 53.67M |
| September 23, 2024 | 53.31M |
| September 20, 2024 | 56.18M |
| September 19, 2024 | 57.62M |
| September 18, 2024 | 57.26M |
| September 17, 2024 | 57.62M |
| September 16, 2024 | 56.54M |
| September 13, 2024 | 58.33M |
| September 12, 2024 | 57.62M |
| September 11, 2024 | 56.90M |
| September 10, 2024 | 57.97M |
| September 09, 2024 | 58.33M |
| September 06, 2024 | 56.54M |
| September 05, 2024 | 57.26M |
| September 04, 2024 | 58.69M |
| September 03, 2024 | 58.69M |
| August 30, 2024 | 60.84M |
| August 29, 2024 | 60.48M |
| August 28, 2024 | 60.84M |
| August 27, 2024 | 60.84M |
| August 26, 2024 | 59.77M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-7.867M
Minimum
May 12 2022
125.77M
Maximum
Mar 22 2024
23.40M
Average
13.36M
Median
Enterprise Value Benchmarks
| Perspective Therapeutics Inc | 530.78M |
| Actinium Pharmaceuticals Inc | -31.21M |
| Chimerix Inc | -59.43M |
| Marinus Pharmaceuticals Inc | 10.41M |
| Jaguar Health Inc | 26.16M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -0.9194M |
| Total Expenses (Quarterly) | 13.70M |
| EPS Diluted (Quarterly) | -0.18 |
| Earnings Yield | -152.2% |